The assessment of the therapeutic effect of bee propolis on oral Lichen Planus treatment.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210112050013N2

Enrollment

Registered

2021-06-30

Start date

2021-07-11

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lichen planus.

Interventions

Intervention 1: Intervention group: Group A consumes Propolis in the form of mouthwash with a dose of 500 mg, according to the manufacturer's instructions once or twice a day after brushing

First rinse the mouth with water or serum (normal saline) and then immediately use mouthwash with a plastic cup on the glass. Each mouthwash should last at least 2-3 minutes. Avoid eating and drinking

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are diagnosed with OLP by an oral specialist. People who have been willing to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: Patients with any past or present immunological disease or disorder. Patients with any past or present allergic disease or disorder. Pregnant and lactating women. Susceptible Patients to bee sting and products. Patients who have used systemic or topical Glucocorticosteroids at least over the past one month. Patients with Lichen Planus extra-oral manifestations. Patients with any continuous medication history. Patients with oral Lichen Planus with evidence of dysplastic changes in the oral mucosa or a history of such changes in the past.

Design outcomes

Primary

Measure	Time frame
Extent of Atrophic areas: The area of Atrophic areas measured by caliper in square millimeters.Extent of Ulcerative areas: The area of the wound area measured by the caliper. Area of Keratotic areas: Area of Keratotic areas measured by caliper. Intensity of pain and irritation: The scale of pain and oral mucosa irritation that the patient reports according to VAS. Timepoint: At the beginning of study and a month after the start of the study. Method of measurement: To measure the area of the affected areas, the largest lesion diameters are measured by a caliper and their product is considered as the area of the target area. If the patient has similar lesions in several areas, the area of all these areas will be added together and this amount will be reported. The scale of pain and irritation is measured by the Visual Analogue Scale. This method of measurement asks the patient to rate their pain and irritation from 0 (with no pain and irritation) to 10 (the most severe pain and irritation).	—

Measure

Time frame

Extent of Atrophic areas: The area of Atrophic areas measured by caliper in square millimeters.Extent of Ulcerative areas: The area of the wound area measured by the caliper. Area of Keratotic areas: Area of Keratotic areas measured by caliper. Intensity of pain and irritation: The scale of pain and oral mucosa irritation that the patient reports according to VAS. Timepoint: At the beginning of study and a month after the start of the study. Method of measurement: To measure the area of the affected areas, the largest lesion diameters are measured by a caliper and their product is considered as the area of the target area. If the patient has similar lesions in several areas, the area of all these areas will be added together and this amount will be reported. The scale of pain and irritation is measured by the Visual Analogue Scale. This method of measurement asks the patient to rate their pain and irritation from 0 (with no pain and irritation) to 10 (the most severe pain and irritation).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Javid Rasekhi

Bojnourd University of Medical Sciences

forooghsajedii12@gmail.com+98 58 3272 9338

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026